Dr. Andy Smith
Life Science Professional
Valuations - current issues in biotech & pharma
Dr. Andy Smith discusses valuations of profitable biotech and pharma companies relative to history, concluding that indications show biotech is too cheap at the current time. The discussion explores the PE values of various companies and how these have changed over time.